Prognostic Value of a Three-DNA Methylation Biomarker in Patients with Soft Tissue Sarcoma

Figure 5

ROC and Kaplan–Meier analyses in groups of patients receiving different adjuvant therapies. (a) and (b) Kaplan–Meier and ROC curves in the group of patients receiving adjuvant pharmaceutical therapy. (c) and (d) Kaplan–Meier and ROC curves in the group of patients receiving adjuvant radiotherapy. It indicates that regardless of the adjuvant treatment therapies the patient received, our biomarker distinguished the high- and low-risk patients significantly.

(a)

(b)

(c)

(d)